ClinicalTrials.gg
CompletedNCT01705145Updated Apr 5, 2016Results posted

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 3 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2016-04-05.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
61st of 84
35 · median 70
Started
2013
with 7 others
Phase 3
45 of 84
none open now
Registered
19th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 61st largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 19th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with cystic fibrosis (CF) who are 2 through 5 years of age and have a CF Transmembrane Conductance Regulator (CFTR) gating mutation in at least 1 allele.

Part A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in participants 2 through 5 years of age and to confirm the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in participants 2 through 5 years of age.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF
  • Must have a CFTR gating mutation in at least 1 allele
  • Aged 2 through 5 years at screening and Day 1
  • Weight >= 8 kg at screening and Day 1
  • Hematology, serum chemistry, coagulation, and vital signs results at screening with no abnormalities that would interfere with the study assessments, as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks before Day 1
  • Abnormal liver function, at screening
  • History of solid organ or hematological transplantation
  • Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1
  • Participation in a clinical study involving administration of either an or a marketed drug within 30 days or 5 terminal half-lives before screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Ivacaftor

    Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than \[\<\] 14 kilograms \[kg\]) or 75 mg (for participants weighing greater than or equal to \[\>=\] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study.. Part B: Ivacaftor 50 mg (for participants weighing \<14 kg) or 75 mg (for participants weighing \>=14 kg) q12h for 24 weeks during Part B of the study.

    Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

    AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants.

    Time frame: Part A: Up to 93 Days

  2. Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

    AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received.

    Time frame: Part B: Up to 28 Weeks

  3. Part A: Plasma Concentration of Ivacaftor and Its Metabolites

    Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor \[M1\] and ivacaftor carboxylate \[M6\]) up to 24 hours post-dose on Day 4 (Hour 0 \[pre-dose\] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period.

    Time frame: Part A: up to 24 hours post-dose on Day 4

Secondary outcomes

  1. Part B: Plasma Concentration of Ivacaftor and Its Metabolites

    Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 \[predose\] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period.

    Time frame: Part B: up to 24 hours post-dose on Day 168

  2. Part B: Absolute Change From Baseline in Sweat Chloride at Week 24

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants.

    Time frame: Part B: Baseline, Week 24

  3. Part B: Absolute Change From Baseline in Weight at Week 24

    Data was reported as per the dose received and for overall participants.

    Time frame: Part B: Baseline, Week 24

  4. Part B: Absolute Change From Baseline in Stature at Week 24

    Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants.

    Time frame: Part B: Baseline, Week 24

  5. Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI = (Weight \[in kg\]) divided by (Stature \[in meters\])\^2. Data was reported as per the dose received and for overall participants.

    Time frame: Baseline, Week 24

07

Results

Posted Apr 24, 2015

Participant flow

Part A
Participant flow — Part A
MilestoneIvacaftor
Started9
Completed9
Not completed0
Part B
Participant flow — Part B
MilestoneIvacaftor
Started34
Completed33
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPart A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants.

Time frame:
Part A: Up to 93 Days
Reported as:
Number · participants
Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs
participantsPart A: Ivacaftor 50 mgPart A: Ivacaftor 75 mgPart A: Overall Ivacaftor
AEs358
SAEs000
Related AEs134
PrimaryPart B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received.

Time frame:
Part B: Up to 28 Weeks
Reported as:
Number · participants
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs
participantsPart B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
AEs102333
SAEs336
Related AEs3811
SecondaryPart B: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 \[predose\] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period.

Time frame:
Part B: up to 24 hours post-dose on Day 168
Reported as:
Mean · ng/mL
Part B: Plasma Concentration of Ivacaftor and Its Metabolites
ng/mLPart B: Overall Ivacaftor
Ivacaftor: Hour 0 on Day 10.00 ± 0.00
Ivacaftor: Hour 0 on Day 14614 ± 590
Ivacaftor: 2 Hours Post-Dose on Day 14932 ± 541
Ivacaftor: 3 Hours Post-Dose on Day 141080 ± 587
Ivacaftor: 6 Hours Post-Dose on Day 141140 ± 627
Ivacaftor: Hour 0 on Day 56448 ± 455
Ivacaftor: 1 Hour Post-Dose on Day 56514 ± 421
Ivacaftor: Hour 0 on Day 112596 ± 747
Ivacaftor: 4 Hours Post-Dose on Day 1121080 ± 835
Ivacaftor: 6 Hours Post-Dose on Day 1121010 ± 885
Ivacaftor: Hour 0 on Day 168500 ± 545
Ivacaftor: 24 Hours Post-Dose on Day 168207 ± 372
M1: Hour 0 on Day 10.00 ± 0.00
M1: Hour 0 on Day 141580 ± 1030
M1: 2 Hours Post-Dose on Day 141870 ± 924
M1: 3 Hours Post-Dose on Day 142280 ± 1140
M1: 6 Hours Post-Dose on Day 142670 ± 1080
M1: Hour 0 on Day 561340 ± 880
M1: 1 Hour Post-Dose on Day 561170 ± 698
M1: Hour 0 on Day 1121680 ± 1360
M1: 4 Hours Post-Dose on Day 1122450 ± 1510
M1: 6 Hours Post-Dose on Day 1122500 ± 1520
M1: Hour 0 on Day 1681460 ± 1200
M1: 24 Hours Post-Dose on Day 168602 ± 647
M6: Hour 0 on Day 10.00 ± 0.00
M6: Hour 0 on Day 141520 ± 1130
M6: 2 Hours Post-Dose on Day 141430 ± 989
M6: 3 Hours Post-Dose on Day 141630 ± 1130
M6: 6 Hours Post-Dose on Day 142090 ± 1350
M6: Hour 0 on Day 561510 ± 1080
M6: 1 Hour Post-Dose on Day 561310 ± 974
M6: Hour 0 on Day 1121660 ± 1130
M6: 4 Hours Post-Dose on Day 1121810 ± 1230
M6: 6 Hours Post-Dose on Day 1122130 ± 1380
M6: Hour 0 on Day 1681520 ± 1130
M6: 24 Hours Post-Dose on Day 168632 ± 465
SecondaryPart B: Absolute Change From Baseline in Sweat Chloride at Week 24

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants.

Time frame:
Part B: Baseline, Week 24
Reported as:
Mean · millimole per liter (mmol/L)
Part B: Absolute Change From Baseline in Sweat Chloride at Week 24
millimole per liter (mmol/L)Part B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
Part B: Absolute Change From Baseline in Sweat Chloride at Week 24-47.07 ± 24.256-46.78 ± 27.584-46.86 ± 26.193
SecondaryPart B: Absolute Change From Baseline in Weight at Week 24

Data was reported as per the dose received and for overall participants.

Time frame:
Part B: Baseline, Week 24
Reported as:
Mean · kilograms (kg)
Part B: Absolute Change From Baseline in Weight at Week 24
kilograms (kg)Part B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
Part B: Absolute Change From Baseline in Weight at Week 241.00 ± 0.4181.50 ± 0.5521.36 ± 0.561
SecondaryPart B: Absolute Change From Baseline in Stature at Week 24

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants.

Time frame:
Part B: Baseline, Week 24
Reported as:
Mean · centimeters (cm)
Part B: Absolute Change From Baseline in Stature at Week 24
centimeters (cm)Part B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
Part B: Absolute Change From Baseline in Stature at Week 242.5 ± 1.453.5 ± 0.933.3 ± 1.17
PrimaryPart A: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor \[M1\] and ivacaftor carboxylate \[M6\]) up to 24 hours post-dose on Day 4 (Hour 0 \[pre-dose\] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period.

Time frame:
Part A: up to 24 hours post-dose on Day 4
Reported as:
Mean · nanogram per milliliter (ng/mL)
Part A: Plasma Concentration of Ivacaftor and Its Metabolites
nanogram per milliliter (ng/mL)Part A: Overall Ivacaftor
Ivacaftor: Hour 0 on Day 10.00 ± 0.00
Ivacaftor: Hour 0 on Day 4396 ± 337
Ivacaftor: 2 Hours Post-Dose on Day 4726 ± 284
Ivacaftor: 3 Hours Post-Dose on Day 4957 ± 283
Ivacaftor: 6 Hours Post-Dose on Day 4542 ± 241
Ivacaftor: 24 Hours Post-Dose on Day 4124 ± 149
M1: Hour 0 on Day 10.00 ± 0.00
M1: Hour 0 on Day 41240 ± 723
M1: 2 Hours Post-Dose on Day 41540 ± 578
M1: 3 Hours Post-Dose on Day 42310 ± 820
M1: 6 Hours Post-Dose on Day 41580 ± 622
M1: 24 Hours Post-Dose on Day 4389 ± 336
M6: Hour 0 on Day 10.00 ± 0.00
M6: Hour 0 on Day 41150 ± 709
M6: 2 Hours Post-Dose on Day 41050 ± 606
M6: 3 Hours Post-Dose on Day 41300 ± 614
M6: 6 Hours Post-Dose on Day 41390 ± 532
M6: 24 Hours Post-Dose on Day 4439 ± 355
SecondaryPart B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI = (Weight \[in kg\]) divided by (Stature \[in meters\])\^2. Data was reported as per the dose received and for overall participants.

Time frame:
Baseline, Week 24
Reported as:
Mean · kilogram per square meter (kg/m^2)
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
kilogram per square meter (kg/m^2)Part B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 240.332 ± 0.53930.314 ± 0.54920.319 ± 0.5378

Adverse events

Collected over Part A: up to 93 days; Part B: up to 28 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Ivacaftor 50 mg—0/4 (0%)3/4 (75%)
Part A: Ivacaftor 75 mg—0/5 (0%)5/5 (100%)
Part A: Overall Ivacaftor—0/9 (0%)8/9 (88.9%)
Part B: Ivacaftor 50 mg—3/10 (30%)9/10 (90%)
Part B: Ivacaftor 75 mg—3/24 (12.5%)23/24 (95.8%)
Part B: Overall Ivacaftor—6/34 (17.6%)32/34 (94.1%)
Most frequent serious events
Most frequent serious events
EventPart A: Ivacaftor 50 mgPart A: Ivacaftor 75 mgPart A: Overall IvacaftorPart B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/40/50/91/101/242/34
Device related sepsisInfections and infestations0/40/50/91/100/241/34
Pseudomonas test positiveInvestigations0/40/50/91/100/241/34
Transaminases increasedInvestigations0/40/50/91/100/241/34
VomitingGastrointestinal disorders0/40/50/90/101/241/34
ConvulsionNervous system disorders0/40/50/90/101/241/34
Most frequent other events
Showing 10 of 88
Most frequent other events
EventPart A: Ivacaftor 50 mgPart A: Ivacaftor 75 mgPart A: Overall IvacaftorPart B: Ivacaftor 50 mgPart B: Ivacaftor 75 mgPart B: Overall Ivacaftor
CoughRespiratory, thoracic and mediastinal disorders0/41/51/94/1015/2419/34
PyrexiaGeneral disorders2/42/54/94/102/246/34
Nasal congestionRespiratory, thoracic and mediastinal disorders0/40/50/94/105/249/34
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/42/52/92/105/247/34
VomitingGastrointestinal disorders0/42/52/93/106/249/34
EcchymosisSkin and subcutaneous tissue disorders0/42/52/90/100/240/34
Upper respiratory tract infectionInfections and infestations0/40/50/91/107/248/34
Rash macularSkin and subcutaneous tissue disorders1/40/51/90/100/240/34
Upper respiratory track congestionRespiratory, thoracic and mediastinal disorders0/41/51/90/101/241/34
Croup infectiousInfections and infestations0/40/50/92/101/243/34

Baseline characteristics

Safety set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Ivacaftor
Part A (n = 9)3.1 ± 1.17
Part B (n = 34)3.2 ± 0.96
Sex/Gender, Customized
Sex/Gender, Customized(participants)Ivacaftor
Part A (n = 9): Female3
Part A (n = 9): Male6
Part B (n = 34): Female6
Part B (n = 34): Male28
08

Study locations

20 sites
  • Birmingham, Alabama, United States
  • Aurora, Colorado, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Pittsburgh, Pennsylvania, United States
  • Salt Lake City, Utah, United States
  • Charlottesville, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Vancouver, Canada
  • Edinburgh, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M; KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016 Feb;4(2):107-15. doi: 10.1016/S2213-2600(15)00545-7. Epub 2016 Jan 21. Erratum In: Lancet Respir Med. 2016 Dec;4(12):e57. doi: 10.1016/S2213-2600(16)30386-1. PubMed 26803277 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2012
First posted
Oct 12, 2012
Start
Jan 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Apr 24, 2015
Last update
Apr 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01705145
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Oct 12, 2012
Start date
Jan 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Apr 24, 2015
Last update
Apr 5, 2016

Study contacts

Margaret Rosenfeld, MD
principal investigator · Seattle Children's Hospital
Jane Davies, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion